134 related articles for article (PubMed ID: 20944102)
1. Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis.
Newbold RF; Mokbel K
Anticancer Res; 2010 Sep; 30(9):3309-11. PubMed ID: 20944102
[TBL] [Abstract][Full Text] [Related]
2. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.
Al Sarakbi W; Sasi W; Jiang WG; Roberts T; Newbold RF; Mokbel K
BMC Cancer; 2009 Aug; 9():290. PubMed ID: 19698110
[TBL] [Abstract][Full Text] [Related]
3. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression.
Kirkpatrick KL; Ogunkolade W; Elkak AE; Bustin S; Jenkins P; Ghilchick M; Newbold RF; Mokbel K
Breast Cancer Res Treat; 2003 Feb; 77(3):277-84. PubMed ID: 12602927
[TBL] [Abstract][Full Text] [Related]
4. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
5. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a tumour suppressor function for DLEC1 in human breast cancer.
Al Sarakbi W; Reefy S; Jiang WG; Roberts T; Newbold RF; Mokbel K
Anticancer Res; 2010 Apr; 30(4):1079-82. PubMed ID: 20530412
[TBL] [Abstract][Full Text] [Related]
7. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
8. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2.
Li H; An J; Wu M; Zheng Q; Gui X; Li T; Pu H; Lu D
Oncotarget; 2015 Sep; 6(29):27847-64. PubMed ID: 26172293
[TBL] [Abstract][Full Text] [Related]
9. SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion.
Chen Z; Raghoonundun C; Chen W; Zhang Y; Tang W; Fan X; Shi X
Biochem Biophys Res Commun; 2018 Apr; 498(3):579-585. PubMed ID: 29522714
[TBL] [Abstract][Full Text] [Related]
10. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
11. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
[TBL] [Abstract][Full Text] [Related]
12. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
[TBL] [Abstract][Full Text] [Related]
13. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.
Parker H; Rose-Zerilli MJ; Larrayoz M; Clifford R; Edelmann J; Blakemore S; Gibson J; Wang J; Ljungström V; Wojdacz TK; Chaplin T; Roghanian A; Davis Z; Parker A; Tausch E; Ntoufa S; Ramos S; Robbe P; Alsolami R; Steele AJ; Packham G; Rodríguez-Vicente AE; Brown L; McNicholl F; Forconi F; Pettitt A; Hillmen P; Dyer M; Cragg MS; Chelala C; Oakes CC; Rosenquist R; Stamatopoulos K; Stilgenbauer S; Knight S; Schuh A; Oscier DG; Strefford JC
Leukemia; 2016 Nov; 30(11):2179-2186. PubMed ID: 27282254
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 1 (IGF-1) and its receptor mRNA levels in breast cancer and adjacent non-neoplastic tissue.
Chong YM; Williams SL; Elkak A; Sharma AK; Mokbel K
Anticancer Res; 2006; 26(1A):167-73. PubMed ID: 16475694
[TBL] [Abstract][Full Text] [Related]
15. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
17. The mRNA expression of hTERT in human breast carcinomas correlates with VEGF expression.
Kirkpatrick KL; Newbold RF; Mokbel K
J Carcinog; 2004 Jan; 3(1):1. PubMed ID: 14738567
[TBL] [Abstract][Full Text] [Related]
18. A New Chromatin-Cytoskeleton Link in Cancer.
Giaccia AJ
Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
[TBL] [Abstract][Full Text] [Related]
19. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Chen R; Zhao WQ; Fang C; Yang X; Ji M
J Cancer; 2020; 11(11):3349-3356. PubMed ID: 32231741
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes.
Xie P; Tian C; An L; Nie J; Lu K; Xing G; Zhang L; He F
Cell Signal; 2008 Sep; 20(9):1671-8. PubMed ID: 18585004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
